Dr Yu Yu graduated in Medical Science (Pharmacology and Biochemistry) from the University of Sydney. She was trained in anti-cancer therapeutics development in the Molecular Pharmacology and Pathology laboratory at the same institution, where she gained a PhD in Medicine (2011). Her postdoctoral training has been conducted in the TeLinde Gynecologic Pathology Laboratory at Johns Hopkins University School of Medicine (United States), with a focus on treatment for recurrent ovarian cancer.
Yu Yu’s primary research goals are dedicated to combatting cancer and its recurrence. She has a keen research interest in experimental therapeutics, with experiences in drug classes that target cellular iron, cytoskeletal dynamics and kinase activities. Some of her studies include investigation on the “omics” mechanism of chemotherapy resistance, orthotopic animal models for recurrent tumours, preclinical research on investigational new drugs and biomarkers to improve pharmacological response, and rational combinatorial therapy for improved patient survival. She has been awarded an Outside-the-Box Grant from the HERA Women’s Cancer Foundation and an Ann Schreiber Mentored Investigator Award from Ovarian Cancer Research Foundation for her research.
Honours, Masters and PhD students with similar reserch interests are encouraged to apply directly email@example.com
2015 Safeway Breast Cancer Poster Award, Safeway
2014 Pathology Young Investigators Day Poster Award, Department of Pathology, Johns Hopkins University
2014 Ann Schreiber Mentored Investigator Award, Ovarian Cancer Research Fund, NY
2012 Peter Doherty Early Career Fellowship, NHMRC. Relinquished in 2013 due to overseas commitment
2011 Peter Bancroft Prize for Research Work, Faculty of Medicine, University of Sydney
2008 University Postgraduate Award Scholarship, University of Sydney
2007 Cancer Institute of New South Wales Research Scholar Award, Australia
2007 Young Investigator Award, Society of Free Radical Research Australasia and Japan
2007 Faculty of Medicine Postgraduate Scholarship, University of Sydney
2007 International Postgraduate Award (IPA), University of Sydney
2007 Endeavour International Postgraduate Research Scholarship (EIPRS), Australian Government
- Suryo Rahmanto, Y., W. Shen, X. Shi, X. Chen, Y. Yu, Z. C. Yu, T. Miyamoto, M. H. Lee, V. Singh, R. Asaka, and 8 more contributors.. "Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming." Nature Communications 11 (1). Inpress.
- Binju, M., M. A. Padilla, T. Singomat, P. Kaur, Y. Suryo Rahmanto, P. A. Cohen, and Y. Yu. 2019. "Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review." Biochimica et Biophysica Acta - General Subjects 1863 (2): 371-378.
- Yu, Y., Y. Suryo Rahmanto, Y. A. Shen, L. Ardighieri, B. Davidson, S. Gaillard, A. Ayhan, X. Shi, J. Xuan, T. L. Wang, and 1 more contributors. 2019. "Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer." EBioMedicine 47: 184-194.
- Alsayed, S. S. R., C. C. Beh, N. R. Foster, A. D. Payne, Y. Yu, and H. Gunosewoyo. 2019. "Kinase targets for mycolic acid biosynthesis in mycobacterium tuberculosis." Current Molecular Pharmacology 12 (1): 27-49.
- Pieterse, Z., M. A. Amaya-Padilla, T. Singomat, M. Binju, B. D. Madjid, Y. Yu, and P. Kaur. 2019. "Ovarian cancer stem cells and their role in drug resistance." International Journal of Biochemistry and Cell Biology 106: 117-126.
- Song, G., L. Chen, B. Zhang, Q. Song, Y. Yu, C. Moore, T. L. Wang, I. M. Shih, H. Zhang, D. W. Chan, and 2 more contributors. 2019. "Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors." Molecular and Cellular Proteomics 18 (3): 448-460.
- Binju, M., M. A. Amaya-Padilla, G. Wan, H. Gunosewoyo, Y. S. Rahmanto, and Y. Yu. 2019. "Therapeutic inducers of apoptosis in ovarian cancer." Cancers 11 (11)
- Zhuang, L., K. T. Lawlor, H. Schlueter, Z. Pieterse, Y. Yu, and P. Kaur. 2018. "Pericytes promote skin regeneration by inducing epidermal cell polarity and planar cell divisions." Life Science Alliance 1 (4)
- Yu, Y., Y. Suryo Rahmanto, M. H. Lee, P. H. Wu, J. M. Phillip, C. H. Huang, M. I. Vitolo, S. Gaillard, S. S. Martin, D. Wirtz, and 2 more contributors. 2018. "Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway." Oncogene 37 (28): 3778-3789.
- Rahmanto, Y. S., X. Shi, W. Shen, T. Miyamoto, Y. Yu, X. Chen, M. H. Lee, V. Singh, M. I. Vitolo, D. Wirtz, and 4 more contributors. 2018. "Inactivation of ARID1A-SWI/SNF complex alters chromatin compactness at enhancer regions and affects transcription of key tumor signaling circuitry." In Annual Meeting of the American-Association-for-Cancer-Research (AACR), Apr 14, 2018, Chicago, IL: AMER ASSOC CANCER RESEARCH.
- Kobayashi, Y., H. Kashima, Y. S. Rahmanto, K. Banno, Y. Yu, Y. Matoba, K. Watanabe, M. Iijima, T. Takeda, H. Kunitomi, and 8 more contributors. 2017. "Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer." Oncotarget 8: 72147-72156.
- Merlot, A. M., N. H. Shafie, Y. Yu, V. Richardson, P. J. Jansson, S. Sahni, D. J. R. Lane, Z. Kovacevic, D. S. Kalinowski, and D. R. Richardson. 2016. "Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase." Biochemical Pharmacology 109: 27-47.
- Yu, Y., S. Gaillard, J. M. Phillip, T. C. Huang, S. M. Pinto, N. G. Tessarollo, Z. Zhang, A. Pandey, D. Wirtz, A. Ayhan, and 3 more contributors. 2015. "Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules." Cancer Cell 28 (1): 82-96.
- Rahmanto, Y. S., S. Bal, K. H. Loh, Y. Yu, and D. R. Richardson. 2012. "Melanotransferrin: Search for a function." Biochimica Et Biophysica Acta - General Subjects 1820 (3): 237-243.
- Yu, Y., E. Gutierrez, Z. Kovacevic, F. Saletta, P. Obeidy, Y. S. Rahmanto, and D. R. Richardson. 2012. "Iron chelators for the treatment of cancer." Current Medicinal Chemistry 19 (17): 2689-2702.
- Yu, Y., Y. S. Rahmanto, and D. R. Richardson. 2012. "Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy." British Journal Of Pharmacology 165 (1): 148-166.
- Yu, Y., Y. S. Rahmanto, C. L. Hawkins, and D. R. Richardson. 2011. "The potent and novel thiosemicarbazone chelators Di-2-pyridylketone-4,4- dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3- thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity." Molecular Pharmacology 79 (6): 921-931.
- Kovacevic, Z., D. S. Kalinowski, D. B. Lovejoy, Y. Yu, Y. S. Rahmanto, P. C. Sharpe, P. V. Bernhardt, and D. R. Richardson. 2011. "The medicinal chemistry of novel iron Chelators for the treatment of cancer." Current Topics In Medicinal Chemistry 11 (5): 483-499.
- Yu, Y., and D. R. Richardson. 2011. "Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1." Journal Of Biological Chemistry 286 (17): 15413-15427.
- Kovacevic, Z., Y. Yu, and D. R. Richardson. 2011. "Chelators to the rescue: Different horses for different courses!." Chemical Research in Toxicology 24 (3): 279-282.
- Yu, Y., and D. Richardson. 2011. "Thiosemicarbazone Iron Chelator." -: LAP Lambert Academic Publishing.
- Singleton, W. C. J., K. T. McInnes, M. A. Cater, W. R. Winnall, R. McKirdy, Y. Yu, P. E. Taylor, B. X. Ke, D. R. Richardson, J. F. B. Mercer, and 1 more contributors. 2010. "Role of glutaredoxin1 and glutathione in regulating the activity of the copper-transporting P-type ATPases, ATP7A and ATP7B." Journal of Biological Chemistry 285 (35): 27111-27121.
- Yu, Y., D. S. Kalinowski, Z. Kovacevic, A. R. Siafakas, P. J. Jansson, C. Stefani, D. B. Lovejoy, P. C. Sharpe, P. V. Bernhardt, and D. R. Richardson. 2009. "Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors." Journal of Medicinal Chemistry 52 (17): 5271-5294.
- Schwab, M. 2008. "Encyclopedia of Cancer.": Springer.
- Kalinowski, D. S., Y. Yu, P. C. Sharpe, M. Islam, Y. T. Liao, D. B. Lovejoy, N. Kumar, P. V. Bernhardt, and D. R. Richardson. 2007. "Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents." Journal of Medicinal Chemistry 50 (15): 3716-3729.
- Yu, Y., Z. Kovacevic, and D. R. Richardson. 2007. "Tuning cell cycle regulation with an iron key." Cell Cycle 6 (16): 1982-1994.
- Yu, Y., J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson. 2006. "Chelators at the cancer coalface: Desferrioxamine to triapine and beyond." Clinical Cancer Research 12 (23): 6876-6883.